Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
56.02
+1.23 (2.24%)
Sep 16, 2025, 2:50 PM EDT - Market open
Guardant Health Stock Forecast
Stock Price Forecast
The 17 analysts that cover Guardant Health stock have a consensus rating of "Strong Buy" and an average price target of $58.24, which forecasts a 3.96% increase in the stock price over the next year. The lowest target is $35 and the highest is $70.
Price Target: $58.24 (+3.96%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Guardant Health stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 10 | 8 | 8 | 7 |
| Buy | 10 | 10 | 10 | 10 | 10 | 10 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 21 | 20 | 18 | 18 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $65 → $70 | Strong Buy | Maintains | $65 → $70 | +24.96% | Sep 4, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $57 → $60 | Buy | Maintains | $57 → $60 | +7.10% | Jul 31, 2025 |
| Raymond James | Raymond James | Buy Maintains $59 → $61 | Buy | Maintains | $59 → $61 | +8.89% | Jul 31, 2025 |
| Mizuho | Mizuho | Buy Maintains $60 → $65 | Buy | Maintains | $60 → $65 | +16.03% | Jun 13, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $50 → $60 | Buy | Maintains | $50 → $60 | +7.10% | May 6, 2025 |
Financial Forecast
Revenue This Year
946.47M
from 739.02M
Increased by 28.07%
Revenue Next Year
1.15B
from 946.47M
Increased by 21.61%
EPS This Year
-3.17
from -3.56
EPS Next Year
-2.58
from -3.17
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 975.0M | 1.2B | |||
| Avg | 946.5M | 1.2B | |||
| Low | 867.3M | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 31.9% | 30.3% | |||
| Avg | 28.1% | 21.6% | |||
| Low | 17.4% | 11.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.77 | -1.44 | |||
| Avg | -3.17 | -2.58 | |||
| Low | -3.19 | -3.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.